Pasithea Therapeutics KTTA Institutional Ownership

Ownership Summary

Pasithea Therapeutics Corp. (NASDAQ:KTTA) has 21 institutional investors that have filed 13F reports for the period ending March 2026.

• Collectively, these holders controlled 61.3% of Pasithea Therapeutics's outstanding shares in March 2026, down from 183.4% in December 2025.
• Their total shares held in KTTA increased 25.65% quarter over quarter, and separately, investors owning Pasithea Therapeutics increased 133.33% from a year ago.
• During the quarter, 10 of these 21 funds increased positions in KTTA, 4 reduced exposure, and 7 held steady.
• Combined, these investors held 14.92Mn shares in KTTA for March 2026, up by 3.05Mn shares quarter on quarter, and up 14.84Mn shares year over year.
• Janus Henderson Group Plc leads ownership in KTTA with 4.2Mn shares as of March 31, 2026, equal to 17.26% of outstanding shares.
• The most significant purchases of KTTA for the quarter ending March 2026 came from Janus Henderson Group Plc (2.1Mn), Cable Car Capital, LP (706.38K), Stonepine Capital Management, LLC (556.24K), RENAISSANCE TECHNOLOGIES LLC (93.4K), VANGUARD CAPITAL MANAGEMENT LLC (53.82K).
• Top sellers of KTTA stock for the quarter ending March 2026 included Ameriprise Financial Inc (579.23K), TWO SIGMA INVESTMENTS, LP (27.72K), Northern Trust Corp (8.72K), Tower Research Capital LLC (TRC) (1.09K).
• Pasithea Therapeutics's 10 largest shareholders as of March 2026 include Janus Henderson Group Plc (4.2Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.1Mn), Vivo Capital, LLC (2.1Mn), Squadron Capital Management LLC (2.1Mn), Ameriprise Financial Inc (1.35Mn), Cable Car Capital, LP (1.21Mn), Stonepine Capital Management, LLC (831.3K), AdvisorShares Investments LLC (337.51K), Persistent Asset Partners Ltd (290.56K), GEODE CAPITAL MANAGEMENT, LLC (103.98K) per Business Quant data.